Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Helsinn Therapeutics begins ROMANA 1 and 2 trials in NSCLC-related cachexia

Aug. 10, 2011

Arena Pharmaceuticals and Eisai report on lorcaserin carcinogenicity study

Aug. 10, 2011

Intercept Pharmaceuticals and Servier enter diabetes collaboration

Aug. 10, 2011

New lysophospholipid S1P1 receptor agonists claimed

Aug. 10, 2011

Zafgen discloses new methionine aminopeptidase 2 inhibitors

Aug. 9, 2011

Novel lysophospholipid S1P1 receptor agonists presented by Sanofi

Aug. 9, 2011

Unigene and GSK enter further agreement for oral PTH analogue

Aug. 9, 2011

Repros Therapeutics reports data from Androxal study in men with type 2 diabetes

Aug. 8, 2011

Palatin Technologies confirms commencement of phase I trial of AZD-2820

Aug. 8, 2011

Pitavastatin is approved in Mexico for hyperlipidemia

Aug. 5, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...